Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares FlyInvestors Business Daily • 10/08/26
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain TherapiesPRNewsWire • 10/08/26
Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive YearPRNewsWire • 09/29/26
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend YieldsBenzinga • 09/23/26
Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea SyndromePRNewsWire • 09/16/26
Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story AliveSeeking Alpha • 09/09/26
VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales JumpZacks Investment Research • 08/06/26
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 08/06/26
Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance MeasuresZacks Investment Research • 08/05/26
Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive PatchPRNewsWire • 07/29/26